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Enforced Expression of GATA-3 During T Cell Development
Inhibits Maturation of CD8 Single-Positive Cells and Induces
Thymic Lymphoma in Transgenic Mice1
Martijn C. Nawijn,* Rita Ferreira,*† Gemma M. Dingjan,* Olev Kahre,‡ Dubravka Drabek,†
Alar Karis,†§ Frank Grosveld,† and Rudolf W. Hendriks2*
The zinc finger transcription factor GATA-3 is of critical importance for early T cell development and commitment of Th2 cells.
To study the role of GATA-3 in early T cell development, we analyzed and modified GATA-3 expression in vivo. In mice carrying
a targeted insertion of a lacZ reporter on one allele, we found that GATA-3 transcription in CD41CD81 double-positive thymo-
cytes correlated with the onset of positive selection events, i.e., TCRab up-regulation and CD69 expression. LacZ expression
remained high (;80% of cells) during maturation of CD4 single-positive (SP) cells in the thymus, but in developing CD8 SP cells
the fraction of lacZ-expressing cells decreased to <20%. We modified this pattern by enforced GATA-3 expression driven by the
CD2 locus control region, which provides transcription of GATA-3 throughout T cell development. In two independent CD2-
GATA3-transgenic lines, ;50% of the mice developed thymic lymphoblastoid tumors that were CD41CD81/low and mostly CD31.
In tumor-free CD2-GATA3-transgenic mice, the total numbers of CD8 SP cells in the thymus were within normal ranges, but their
maturation was hampered, as indicated by increased apoptosis of CD8 SP cells and a selective deficiency of mature
CD69lowHSAlow CD8 SP cells. In the spleen and lymph nodes, the numbers of CD81 T cells were significantly reduced. These
findings indicate that GATA-3 supports development of the CD4 lineage and inhibits maturation of CD8 SP cells in the
thymus. The Journal of Immunology, 2001, 167: 715–723.
I n the thymus early CD42CD82 double-negative (DN)3 pre-cursors develop into mature CD4 or CD8 single-positive (SP)T cells following a tightly regulated program of cellular dif-
ferentiation (1–4). The DN population is generally subdivided into
four distinct developmental stages, defined by differential expres-
sion of the surface markers IL-2Ra chain CD25 and phagocyte
glycoprotein 1 CD44 (5). Precursor T cells rearrange their TCRb
genes during the CD251CD442 DN stage, and only those cells
that produce a functional TCRb protein proceed via a proliferative
phase to the CD252CD442 DN stage (3, 6, 7). These cells rapidly
up-regulate CD4 and CD8 and start to rearrange their TCRa genes.
After successful TCRa rearrangement, TCRab-bearing immature
cells are selected for MHC recognition during the process of pos-
itive selection (8–10). Concomitantly, developing T cells will un-
dergo lineage commitment to ensure the correlation of the TCR
specificity for MHC class I with the CD8 lineage and for MHC
class II with the CD4 lineage (2, 11, 12). In addition, potential
self-reactive T lymphocytes are eliminated by selection against
self-recognition within the MHC context (13).
T cell development is regulated by a large number of transcrip-
tion factors (14, 15). One of the transcription factors critically
involved in T cell development is GATA-3, which was originally
identified in the T cell lineage as a protein that binds to the TCRa
gene enhancer (16). GATA-3 is a member of a family of transcrip-
tion factors that bind a GATA consensus motif through a highly
conserved C4 zinc finger binding domain (17). Mice with a tar-
geted deletion of GATA-3 display massive internal bleeding and
central nervous defects and die between embryonic days 11 and 12
due to noradrenaline deficiency (18, 19). GATA-32/2 fetuses that
were pharmacologically rescued by feeding catechol intermediates
to pregnant females displayed severe thymic hypoplasia at fetal
day 16.5 (19). GATA-3 expression is abundant in the developing
CNS, adrenal gland, and kidney. Within the hemopoietic system,
GATA-3 expression is confined to T lymphocytes (18, 20–23). In
mature Th cells, GATA-3 has been shown to be essential for Th2
differentiation (24–26) and has been implicated in the regulation of
locus accessibility of the IL-4, IL-5, and IL-13 genes by chromatin
remodeling (27–29).
The GATA-3 gene is expressed in common lymphoid progeni-
tors and in the earliest CD252CD441 DN progenitors in day 12
fetal thymus (23, 30). Antisense GATA-3 oligonucleotides inhib-
ited T cell development from fetal liver precursors in fetal thymic
organ cultures, indicating the critical importance of GATA-3 for
early T cell development (30). Moreover, RAG-22/2 complemen-
tation experiments in vivo demonstrated that the development of
GATA-32/2 embryonic stem (ES) cell-derived T cell precursors is
arrested at or before the DN stage (31). In such GATA-32/2/RAG-
22/2 chimeric mice, the GATA-3-deficient ES cells contributed
significantly to nonhemopoietic tissues and to the erythroid, my-
eloid and B cell lineages. In chimeric mice generated by injection
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of GATA-3-deficient lacZ-expressing ES cells in wild-type blasto-
cysts, we previously showed that GATA-32/2 ES cells did not
contribute to the T cell lineage, not even to the earliest subset of
CD252CD441 DN thymic progenitors (22).
Because GATA-32/2 cells display a block before the earliest T
cell progenitor, few data are available on the role of GATA-3
during T cell development in the thymus. Using mice with an
insertion of a lacZ reporter in the GATA-3 gene on one allele
(GATA-31/nlslacZ), we examined the proportion of GATA-3-ex-
pressing cells as a function of T cell development (22). We found
significant GATA-3 expression at the earliest DN stage in the thy-
mus. The two waves of TCRb and TCRa gene recombination were
associated with low proportions of lacZ1 cells. The stage of rap-
idly proliferating CD442CD252 DN cells, which insulates these
two periods of TCR rearrangement, was characterized by a large
proportion of lacZ-expressing cells. The proportion of lacZ1 cells
increased again as double-positive (DP) cells progressed into CD4
or CD8 SP cells. The presence of significant proportions of lacZ1
cells within the CD8 SP T cell subpopulation in the thymus was in
strong contrast with the almost complete absence of lacZ expres-
sion in mature CD81 T cells in the periphery (22).
The differential regulation of GATA-3 gene expression in the
CD4 vs the CD8 lineage prompted us to investigate its expression
during positive selection and CD4/CD8 lineage commitment in the
thymus in more detail. We analyzed the GATA-31/nlslacZ mice us-
ing additional markers for the maturation stages of DP and SP
cells, including CD3, TCRab, heat-stable Ag (HSA), CD62 L-
selectin (CD62L), and particularly CD69, which is typically in-
duced by TCR signaling and therefore marks cells that are in the
process of positive selection (32–36). In addition, we investigated
the functional role of GATA-3 during T cell development in vivo
by the generation of transgenic mice with enforced GATA-3 ex-
pression driven by the human CD2 locus control region (LCR),
which provides expression of the GATA-3 transgene throughout T
cell development (37).
Materials and Methods
Mice
The GATA-31/nlslacZ mice in which one GATA-3 allele was replaced by a
lacZ reporter have been described previously (22). For the generation of the
CD2-GATA3 construct, the translation initiation site was mutated (ATG to
GTG) in a murine GATA-3 cDNA clone and three hemagglutinin (HA)
epitope tags were added along with a new ATG and Kozak’s consensus
sequence. Subsequently, the ;2-kb mGATA-3 was cloned into a human
CD2 mini-gene Bluescript SK vector, with ;5 kb of CD2 59 promoter
sequence and ;5.5 kb of 39 CD2 flanking sequences (38). The latter con-
tained the 39 untranslated sequence and poly(A) addition site of the CD2
gene, as well as the LCR, which was shown to confer T cell-specific,
copy-dependent, integration site-independent expression in transgenic
mice (37). A 13.2-kb linear fragment was injected into pronuclei of FVB 3
FVB fertilized oocytes at a concentration of ;2 ng/ml. Founder mice were
identified by genomic Southern blotting and crossed onto an FVB back-
ground. To determine the genotype of the subsequent generations, tail
DNA was analyzed by Southern blotting of either EcoRI/XbaI double di-
gests hybridized to a 2-kb HindIII CD2 LCR probe (39) or EcoRI digests
hybridized to a 800-kb partial GATA-3 cDNA probe (21).
Western blotting analyses
Total nuclear protein extracts were prepared according to Andrews and
Faller (40). Protein concentration in the nuclear extracts was determined
using the bicinchoninic acid protein assay (Pierce, Rockford, IL). For
Western blotting analysis, 50 mg of total nuclear protein was loaded per
lane and separated on 10% SDS-PAGE gels under reducing conditions and
transferred to polyvinylidene difluoride membrane (Immobilon-P; Milli-
pore, Bedford, MA). Blots were blocked with 2% BSA in PBS (pH 7.0)/
0.05% Tween 20 and incubated with first- and second-step reagents in 2%
nonfat dry milk in PBS (pH 7.0)/0.05% Tween 20. The mouse anti-
GATA-3 mAb Hg-3-31 and the polyclonal rabbit-anti-HA Ab Y11 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Second-step
reagents were HRP-conjugated goat anti-mouse Ig and swine anti-rabbit Ig
from Dako (Glostrup, Denmark). Peroxidase activity was visualized by
ECL using standard procedures.
Flow cytometric analyses
The preparation of single-cell suspensions, determination of b-galactosi-
dase activity using fluorescein-di-b-D-galactopyranoside (FDG), mAb in-
cubations, and three- or four-color cytometry have been described previ-
ously (41). The following mAb were purchased from BD PharMingen (San
Diego, CA): FITC-conjugated anti-CD3e and anti-TCRab, PE-conjugated
anti-CD4 (L3T4), anti-CD24/HSA, anti-CD25 (clone 3C7), anti-CD62L
and anti-CD69, CyChrome-conjugated anti-CD4, anti-CD8 and anti-CD44,
biotinylated anti-CD4 and anti-CD8, APC-labeled anti-CD3e, and anti-
CD4. Secondary Abs used were PE-, TriColor-, or APC-conjugated
streptavidin (Caltag, Burlingame, CA). FDG and To-Pro3 were purchased
from Molecular Probes Europe (Leiden, The Netherlands). FITC-labeled
annexin V was obtained from Nexins Research (Hoeven, The Netherlands).
For intracellular detection of GATA-3 protein, cells were fixed and per-
meabilized using paraformaldehyde and saponin as described previously
(42) and subsequently incubated with the Hg-3-31 anti-GATA-3 mAb
(Santa Cruz Biotechnology) and FITC-labeled anti-mouse IgG1 (BD
PharMingen) as a second step.
Simultaneous two-color staining of membrane CD4 and CD8, combined
with a TUNEL technique to quantify apoptosis, was performed using flu-
orescein in situ cell death detection (Roche Molecular Biochemicals,
Mannheim, Germany) as described elsewhere (43).
Results
GATA-3 expression is strongly induced during positive selection
of developing T cells
We have previously quantified the GATA-3 expression profile dur-
ing T cell development in vivo by placing a lacZ reporter gene,
containing a nuclear localization signal, under direct GATA-3
transcriptional control. In these GATA-31/nlslacZ mice, GATA-3-
directed lacZ expression was analyzed by flow cytometry using
FDG as a b-galactosidase substrate, and differential expression of
GATA-3 in DP (;16% lacZ1 cells), CD4 SP (;84%), and CD8 SP
(;33%) cells was found (22). Since it has been shown that DP T
cells differentiate into mature SP T cells via a series of phenotyp-
ically distinct subpopulations, reflecting the multistage process of
positive selection and CD4/CD8 lineage commitment (2, 11, 12),
we investigated GATA-3 gene expression in these subpopulations
in more detail.
Upon MHC-TCRab interaction in DP cells, the surface ex-
pression of the CD69 marker is up-regulated (32–35), followed
by a down-regulation of the CD4/CD8 coreceptor surface ex-
pression (2). Therefore, we analyzed lacZ activity in conjunc-
tion with surface expression of CD4, CD8, and CD69 (Fig. 1).
The majority of DP cells (;85%) did not express CD69 on the
cell surface and in this CD692 DP population lacZ was ex-
pressed in ;19% of cells. By contrast, within the CD691 DP
subpopulation, lacZ was expressed in ;54% of the cells. After
subsequent down-regulation of coreceptor expression and tran-
sition into the CD4lowCD8low subpopulation, ;80% of the
CD691 cells expressed lacZ (Fig. 1). The CD4lowCD8low cells
have been shown to subsequently enhance CD4 expression (2),
thereby developing into the CD41CD8low subset, which still
contains precursors for both CD4 and CD8 SP T cells (2, 44 –
46). LacZ expression was present in ;86% of these
CD41CD8lowCD691 cells (Fig. 1). In addition, we found that
in the DP, CD4lowCD8low, and CD41CD8low subpopulations,
lacZ expression correlated with the expression levels of TCRab
or CD3 on the cell surface (shown for TCRab in Fig. 1A).
These results indicated that the induction of GATA-3 transcrip-
tion coincides with CD3 and TCRab up-regulation and CD69
expression in DP cells.
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GATA-3 gene expression is down-regulated after commitment to
the CD8 lineage
Bipotential CD41CD8lowCD691 T cells differentiate into either
CD4 or CD8 SP cells by shutting down expression of the recip-
rocal coreceptor gene (2, 44–46). Final maturation of SP thymo-
cytes is accompanied by down-regulation of CD69 and HSA on
the cell surface and induction of high-level expression of CD62L
and CD44 (36, 47, 48).
As shown in Fig. 1, lacZ expression was present in ;87% of the
cells committed to the CD4 lineage (CD41CD82CD691TCRabhigh
cells) and in ;78% of the more mature CD41 cells with a
CD692HSAlow surface profile. By contrast, during the maturation of
CD8 lineage cells, ;40% of the CD691HSA1 and only ;16% of the
mature CD692HSAlow CD81TCRabhigh cells expressed lacZ. Like-
wise, lacZ expression was found to be significantly down-regulated in
mature CD441 and CD62L1CD81 cells (data not shown). The in-
tensities of the fluorescence signals show that the lacZ expression
levels per cell increased slightly during the maturation process of CD4
SP cells, whereas CD8 SP cells displayed lower and more heteroge-
neous lacZ expression levels (Fig. 1A).
When the T cells leave the thymus, the proportions of
GATA-31 cells decrease to ;20% of the CD41 and to ,1% of the
CD81 T cell populations in the spleen and lymph nodes (22). For
the CD41 lineage cells in the spleen, we did not observe a clear
correlation between GATA-3 and the expression of the HSA,
CD69, CD44, CD62L, or CD25 surface markers, which are instru-
mental to specify subpopulations of naive, activated, or memory T
cells (49, 50).
As summarized in Fig. 1B, the proportions of GATA-3-express-
ing cells were low in CD32TCRab2CD692 DP cells (;19%) and
increased at the onset of positive selection events characterized by
up-regulation of CD3 and TCRab surface expression and induc-
tion of CD69. The proportions increased to ;86% at the stage of
the last uncommitted subset of CD41CD8lowCD691cells and re-
mained high for the most mature thymic CD692CD41 subpopu-
lation. By contrast, commitment to the CD8 lineage was associated
with down-regulation of GATA-3 expression, resulting in ,20%
GATA-31 cells within the mature population of CD692CD81
cells.
Transgenic expression of GATA-3 driven by the human CD2
LCR
To modify GATA-3 expression in vivo, transgenic mice were gen-
erated in which the murine GATA-3 gene, 59 tagged with three HA
epitopes, was expressed under the control of the human CD2 LCR
(38). Two independent CD2-GATA3-transgenic lines, TgA and
TgB, were established that appeared to contain comparable num-
bers of transgene copies (data not shown). No differences were
found between the two lines in any of the performed analyses. The
offspring did not manifest developmental defects or any increased
susceptibilities to infectious disease or malignancies for over 9 mo
of age, with the exception of the observed thymic lymphomas dis-
cussed below.
Expression of the CD2-GATA3 transgene was analyzed in var-
ious lymphoid tissues by comparing transgenic and nontransgenic
littermates. Western blotting experiments were performed on nu-
clear protein extracts from 2- to 3-mo-old mice using a mouse
mAb specific for GATA-3 and a polyclonal Ab specific for the HA
tag. The endogenous GATA-3 gene encodes a ;47-kDa protein
that was detected in nuclear extracts from thymus and spleen of
wild-type as well as CD2-GATA3-transgenic mice (Fig. 2A). The
anti-GATA-3 Ab also detected a slightly larger ;51-kDa band in
the thymus samples from mice of both transgenic lines. Compar-
ison of the intensities of the ;47- and ;51-kDa GATA-3-specific
bands in these nuclear protein extracts from thymus samples
showed that the expression level of the 3XHA-GATA-3 transgene-
encoded protein was similar to that of the endogenous GATA-3
protein. In contrast, in the spleen samples, the ;51-kDa GATA-
3-specific band was very weak or absent (Fig. 2A). The ;51-kDa
band in the thymus extracts of transgenic mice was also recognized
by Ab against the HA tag, but the expression levels of transgene-
encoded GATA-3 protein in the spleen and lymph node extracts
were very low and often almost undetectable by Western blotting
analyses (Fig. 2B).
To further investigate differential expression of GATA-3 in the
individual stages of T cell development, intracellular flow cytom-
etry experiments were performed using the mouse monoclonal an-
tiserum specific for GATA-3. Although this technique is limited by
a background signal of the GATA-3 Ab, it allows a comparison of
GATA-3 expression levels in nontransgenic and CD2-GATA3-
transgenic mice in separate T cell subpopulations. In the wild-type
FIGURE 1. Analysis of lacZ expression in thymocytes from GATA-31/nlslacZ
mice by four-color flow cytometry. A, Thymus cell suspensions were
loaded with the b-galactosidase substrate FDG and subsequently stained
with anti-CD4 and anti-CD8 in combination with anti-CD69, anti-TCRab,
or anti-HSA Abs. Cells were analyzed for the expression of CD4 and CD8,
the indicated subpopulations A–E were gated and analyzed for lacZ ex-
pression and the fourth surface marker (CD69, TCRab, or HSA). The
numbers indicate the percentage of lacZ-expressing cells in the subpopu-
lations analyzed. All samples are lymphocyte gated by FSC and side scat-
ter. B, Overview of the proportions of lacZ-expressing cells in the indicated
thymocyte subpopulations in GATA-31/nlslacZ mice. The numbers are mean
values 6 SD (n 5 3). The background percentages of b-galactosidase-
positive cells, as determined in wild-type control mice, was ,1% in all
subpopulations.
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animals, the GATA-3 levels were low in DP cells, increased dur-
ing positive selection in CD4lowCD8low cells, and were high in
CD4 SP cells (Fig. 2C), consistent with our findings in the GATA-
31/nlslacZ mice (Fig. 1). Expression of the CD2-GATA3 transgene
was determined by comparison of the mean fluorescence intensi-
ties of intracellular GATA-3 staining in histogram overlays of
transgenic and nontransgenic mice, revealing substantial GATA-3
overexpression in most thymocyte subpopulations (Fig. 2C).
GATA-3 protein levels were uniformly higher in DP,
CD4lowCD8low, CD41CD8low, and CD4 SP thymic subpopula-
tions from CD2-GATA3-transgenic mice as compared with wild-
type mice. By contrast, for the CD8 SP cells in the thymus and the
CD41 or CD81 T cells in the spleen, GATA-3 levels in the CD2-
GATA3-transgenic mice were close to those observed in wild-type
littermates. Therefore, these findings confirm the very low expres-
sion levels of the transgene-encoded GATA-3 protein in peripheral
T cells that were observed in the Western blotting experiments.
Since CD2 surface expression in the individual T cell subpopulations
in thymus and spleen was comparable (data not shown), the observed
modulated GATA-3 protein expression profile in the transgenic mice
does not appear to reflect the activity of the CD2 LCR.
Collectively, these data show that the presence of the CD2-
GATA3 transgene resulted in a modification of the expression pat-
tern of GATA-3 during T cell development, without extreme over-
expression of GATA-3 protein in any of the thymic
subpopulations. Especially in the DP population, which normally
show little GATA-3 expression, the presence of the CD2-GATA3
transgene strongly increased the GATA-3 protein levels.
CD2-GATA3-transgenic mice have decreased CD81 T cell
numbers in the periphery
To analyze the effect of the CD2-GATA3 transgene on T cell de-
velopment, we examined the T cell populations in thymus, spleen,
and mesenteric lymph nodes from 2- to 3-mo-old CD2-GATA3-
transgenic mice and nontransgenic littermates by flow cytometry
(Fig. 3). In the CD2-GATA3 mice, the sizes of the main thymocyte
subpopulations, the DN, DP, and SP cells, were within the normal
ranges, indicating that the enforced GATA-3 expression did not
dramatically impede thymocyte development (Fig. 3). Moreover,
thymus cellularity was not significantly different between trans-
genic mice (99 6 34 3 106, n 5 21) and nontransgenic littermates
(103 6 37 3 106, n 5 14). No significant differences were de-
tected between CD2-GATA3-transgenic mice and normal litter-
mates within the DN subpopulations as defined by differential
CD44 and CD25 expression (data not shown). In contrast, the
CD2-GATA3-transgenic mice had fewer CD81 T cells (;50% of
control) in spleen and lymph nodes (shown for spleen in Fig. 3).
The residual transgenic CD81 T cells present exhibited a more
heterogeneous CD8 expression and higher CD3 expression on the
cell surface. The numbers of CD41 T cells in the periphery were
comparable between the two groups of mice.
Taken together, these results indicated that enforced expression
of GATA-3 did not result in detectable adverse effects on CD41 T
cell development in 2- to 3-mo-old CD2-GATA3-transgenic mice.
FIGURE 2. Expression of GATA-3 in lymphoid organs of wild-type
and CD2-GATA3-transgenic mice. A, Western blotting analyses of
GATA-3 protein expression in total nuclear protein extracts from thymus
and spleen from wild-type (wt) and CD2-GATA3-transgenic mouse lines
(tgA and tgB) as detected by anti-GATA-3 Abs (;47-kDa band, endoge-
nous (endo.) GATA-3; ;51-kDa band, transgenic (trans.) GATA-3). B,
Western blotting analyses of GATA-3 protein expression in nuclear ex-
tracts from the indicated tissues from wild-type and CD2-GATA3 tgA mice.
GATA-3 is detected by anti-GATA3 Abs (upper half) or anti-HA Abs
(lower half). In the anti-HA blot, thymus and spleen cell extracts from both
nontransgenic and CD2-GATA3 transgenic mice displayed two weak back-
ground bands, just above the ;51-kDa HA-GATA-3 band. C, Cell sus-
pensions were stained for surface CD3, CD4, and CD8 expression, and
subsequently for intracellular GATA-3 protein. The indicated T cell sub-
populations were gated and analyzed for GATA-3 expression. The results
are displayed as histograms of CD2-GATA3-transgenic mice (bold lines)
along with those of nontransgenic control mice (thin lines). CD42CD82
populations were gated on CD32 cells. CD4lowCD8low cells and
CD41CD8low were gated on CD31 cells. The numbers indicate the mean
fluorescence intensities in nontransgenic (normal type) and CD2-GATA3-
transgenic mice (bold type). Data shown are representative of six mice
examined within each group.
FIGURE 3. Phenotype of CD2-GATA3-transgenic mice. T cell devel-
opment in the presence of the CD2-GATA3 transgene results in reduced
numbers of peripheral CD81 cells. Flow cytometric analyses of the thymus
and spleen of 2-mo-old wild-type and CD2-GATA3 mice. Single-cell sus-
pensions were stained with anti-CD3, anti-CD4, and anti-CD8 Abs. Results
are displayed as dot plots of lymphocyte gate cells; percentages of total
cells within the indicated quadrants are given. Data shown are representa-
tive of .20 mice examined within each group.
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In contrast, mature CD8 SP cells manifested decreased survival,
either within the thymus or shortly after leaving the thymus.
CD2-GATA3-transgenic mice develop thymic lymphomas
When the CD2-GATA3-transgenic mice were followed up to 9 mo
of age, ;50% (26 of 51) developed thymic lymphomas (Fig. 4A).
Typically, these lymphomas were noticed as mice displayed re-
spiratory distress at the age of 6–8 mo, but in three cases such
animals were observed at ;3 mo of age. Tumor frequencies in the
two independent transgenic lines were similar, whereas tumors
were not seen in nontransgenic littermates. Several animals with a
thymic lymphoma exhibited enlargement of spleen or lymph
nodes. Lymphoma cells were found to be present in the spleen,
liver, lymph nodes, and kidney, indicating that the thymic lym-
phomas metastasized to the periphery. This was confirmed by the
presence of identical clonal TCRb rearrangement patterns in
Southern blotting analyses using probes specific for Jb1 or Jb2 gene
segments (Fig. 4B). In a fraction of the tumors analyzed, we ob-
served Jb2 restriction fragment patterns that would be consistent
with biclonality (see Fig. 4B, TL5). Often particular restriction
fragments were lost in metastases, suggesting ongoing TCRb re-
arrangement or deletion (see Fig. 4B, compare thymus and lymph
node of TL2).
When tumor cell samples from thymus, spleen, or lymph node
were analyzed for the expression of GATA-3 in Western blotting
experiments, high levels of transgenic HA-tagged GATA-3 were
observed, often accompanied by high endogenous GATA-3 ex-
pression (Fig. 4C). The ratio between transgenic and endogenous
GATA-3 varied, not only between individual tumors but also be-
tween different metastases of a single tumor (see Fig. 4C, compare
mesenteric lymph node and spleen of TL 9).
Flow cytometric analyses demonstrated that the thymic lympho-
mas consisted of CD41 lymphoblasts with variable levels of CD8
coexpression. Fig. 5A illustrates four examples of thymic lympho-
mas (CD41CD81/low cells), with different metastases in lymph
nodes and spleen, showing the variability of surface CD4 and CD8
expression on the malignant cells. Immunohistochemical exami-
nation of thymic tumor tissue sections confirmed that the tumors
mainly consisted of CD41CD81 lymphoblasts. Most of the tumors
contained areas that had lost expression of CD8 and sometimes
FIGURE 4. Characteristics of thymic lymphomas in CD2-GATA3-
transgenic mice. A, Survival of wild-type mice (gray line, n 5 42) and
CD2-GATA3-transgenic mice (black line, n 5 51), followed for 38 wk in
a Kaplan-Meier curve as fraction of the total numbers of mice. B, Southern
blotting analysis of TCRb rearrangements in various lymphoblastoid tumor
samples. EcoRI digests were hybridized to a TCR Jb2 probe. T, Thymus;
S, spleen; L, lymph node. p, Position of the germline 2.4-kb EcoRI frag-
ment; on the left the positions of l X BsteII restriction fragments are
indicated in kb. C, Western blotting analyses of GATA-3 protein expres-
sion in total nuclear extracts from the indicated tumor tissues as detected by
anti-GATA-3 Abs. trans., ;51-kDa transgenic GATA-3; endo., ;47-kDa
endogenous GATA-3; T, thymus; S, spleen; M, mesenteric lymph node; L,
axillary lymph node.
FIGURE 5. Surface profile of lymphoblastoid tumor cells in CD2-GATA3-
transgenic mice. A, Flow cytometric analyses of four different CD41CD81/low
thymic lymphoma primary tumor samples as well as metastases present in
lymph node and spleen. B, Identification of an atypical GATA-
3highCD31CD41CD8low lymphoblastoid cell population in the thymus of a
CD2-GATA3-transgenic mouse, indicative for a thymic lymphoma (TL7).
Nontransgenic and tumor-free CD2-GATA3-transgenic mice are shown as
controls. Results are displayed as dot plots for CD4 and CD8. The given
percentages of the gated CD41CD8low populations are of all thymocytes. C,
Analysis of FSC, CD3, and intracellular GATA-3 expression in the gated
CD41CD8low thymocyte subpopulation shown in B. The results are displayed
as histograms of the CD2-GATA3-transgenic TL7 mouse (bold lines) along
with those of a nontransgenic (dashed lines) and a tumor-free CD2-GATA3-
transgenic mouse (thin lines). Cell suspensions were stained for CD3, CD4,
and CD8 and subsequently for intracellular GATA-3. All samples are lym-
phocyte/lymphoblast gated by FSC and side scatter.
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also CD4. A network of MHC class II-negative fibroblasts sup-
ported these lymphoblasts, whereas characteristic structures of ep-
ithelial cells expressing cortical or medullar cell markers were ab-
sent (data not shown).
Among CD2-GATA3-transgenic mice that did not exhibit out-
ward signs of illness nor manifested a macroscopically visible thy-
mic tumor at ;3 mo of age, we found evidence for early stages of
tumor development in 6 of 32 cases (;19%). In flow cytometric
analyses of thymus cell suspensions, the CD41CD81/low subsets
contained atypical fractions of CD31 lymphoblastoid cells with
high forward scatter (FSC) characteristics suggestive of tumor
growth. In the example shown in Fig. 5, B and C, the lymphoblas-
toid cells had a CD31CD41CD8low phenotype and expressed high
levels of GATA-3 protein, as determined by intracellular flow cy-
tometry. In these lymphoblastoid cells, CD69 expression was vari-
able (data not shown).
These findings indicate that dysregulation of GATA-3 expres-
sion results in the formation of lymphoblastoid tumors at a specific
stage of thymic development, i.e., the CD41CD81/low thymocyte
subpopulation.
GATA-3 enhances TCRab up-regulation during positive
selection
As we observed a correlation between GATA-3 expression and
TCRab or CD3 surface levels in GATA-31/nlslacZ mice, we inves-
tigated these parameters in the thymocyte subpopulations of the
CD2-GATA3 mice (Fig. 6A). The expression of CD69 in the DP,
CD4lowCD8low, and CD41CD8low subpopulations was similar in
CD2-GATA3 and wild-type mice. In contrast, the proportions of
TCRabhigh or CD3high cells were significantly increased in CD2-
GATA3 mice, particularly in the CD691CD4lowCD8low subpopu-
lation (shown for TCRab expression in Fig. 6A). In the more ma-
ture fractions of CD4lowCD81 and SP cells, the expression levels
of CD3 and TCRab were similar in transgenic animals and wild-
type littermates.
We noticed that in the CD2-GATA3-transgenic mice, the cells
within the DP subpopulations had increased average FSC values
closer to those of normal SP cells (Fig. 6B). The increased size of
CD2-GATA3-transgenic DP cells did not reflect an enhanced ac-
tivation status of these cells, as we failed to detect activated cells
with high Th2 cytokine production (26) in immunohistochemical
analyses of the thymi of CD2-GATA3 mice. We also did not find
evidence for a direct effect of transgenic GATA-3 on the cell cycle
in DP cells, as flow cytometric analyses, using anti-CD4, anti-
CD8, and To-Pro3, did not reveal differences in the cell cycle
between CD2-GATA3-transgenic animals and their wild-type lit-
termates (data not shown). The development of CD3/TCRablow
DP into CD3/TCRabhigh SP cells is normally accompanied by an
increase in the average cell size. Therefore, the findings of the
small increase in DP cell size and the slightly accelerated up-reg-
ulation of surface TCRab and CD3 expression in CD2-GATA3-
transgenic mice suggest that enforced GATA-3 expression may
influence the kinetics of positive selection.
GATA-3 inhibits maturation of CD8 SP T cells
As the reduction of peripheral CD81 T cell numbers in the CD2-
GATA3 transgenic mice suggested increased cell death or ham-
pered maturation of CD8 SP cells in the thymus, we analyzed the
thymic CD8 SP compartment in more detail and specifically eval-
uated the final maturation steps of CD8 SP cells.
To analyze the extent of apoptosis in the SP subpopulations, we
determined the fraction of cells that were annexin V-positive in
CD2-GATA3-transgenic mice and their nontransgenic littermates.
In addition, we performed TUNEL assays in conjunction with sur-
face CD4/CD8 staining. Using these techniques, we found that the
thymi of CD2-GATA3-transgenic mice contained higher numbers
of apoptotic cells, not only in the CD8 SP but to some extent also
in the CD4 SP subpopulations (Fig. 7, A and B).
It has been reported that final maturation of SP T cells is ac-
companied by a down-regulation of CD69 and HSA expression
(36, 48). The enforced GATA-3 expression appeared to inhibit the
final maturation of CD81 cells, as a selective deficiency of
CD69lowHSAlow cells was observed, when CD2-GATA3-trans-
genic and wild-type littermates were compared (Fig. 7C). For
CD41 cells, the enforced GATA-3 expression only mildly affected
the final thymic maturation steps. In addition, in the CD2-GATA3-
transgenic mice an increase in the surface expression of CD44, a
marker for activated or memory T cells, was observed both in the
CD4 and the CD8 SP population (Fig. 7C). This phenomenon was
also seen in the mature CD41 and CD81 T cells in the spleen (see
accompanying paper). Finally, the expression of L-selectin
(CD62L), a marker which is expressed at high levels on naive T
cells and which is essential for homing to peripheral lymphoid
organs (51), was comparable in transgenic and nontransgenic an-
imals. Therefore, the decrease in peripheral CD81 T cell numbers
in CD2-GATA3-transgenic mice cannot be explained by a reduced
capacity of the mature CD8 SP T cells to leave the thymus.
In summary, we observed a substantial increase of apoptotic
CD8 SP cells and a decrease of mature CD69lowHSAlow cells in
the thymic CD8 SP subpopulation, as well as reduced numbers of
CD81 T cells in the peripheral organs. These findings indicate that
enforced GATA-3 expression resulted in a partial differentiation
arrest of CD81 cells associated with significant cell death in the
thymus.
Discussion
In this report, we have used two different mouse models to study
the role of GATA-3 in early T cell development in vivo. We eval-
uated GATA-3-directed lacZ expression in GATA-31/nlslacZ mice
FIGURE 6. The CD2-GATA3 transgene enhances TCRab up-regula-
tion during positive selection. A, Cell suspensions were stained for CD4,
CD8, and CD69 expression along with either CD3 or TCRab. The indi-
cated T cell subpopulations (see also Fig. 1A) were gated and analyzed for
TCRab expression. The results are displayed as histograms of CD2-
GATA3-transgenic mice (bold lines) along with those of nontransgenic
control mice (thin lines). The percentages shown are the fractions of the
CD691CD4lowD8low cells that are in the indicated TCRabhigh gate in wild-
type mice (below marker) and CD2-GATA3-transgenic mice (above
marker, bold type). B, The effect of the CD2-GATA3 transgene on the cell
sizes of the DP thymocyte subpopulation. Cell suspensions were stained for
CD4 and CD8. DP cells were gated and analyzed for FSC; the results are
displayed as histogram overlays of a CD2-GATA3-transgenic (bold line)
and nontransgenic control (thin line) mouse.
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and examined the effects of enforced GATA-3 expression through-
out T cell development in CD2-GATA3-transgenic mice in which
GATA-3 transcription is driven by the CD2 LCR.
Our findings implicate GATA-3 as a participant in the commit-
ment process to the CD4 vs the CD8 lineage. First, we found that
commitment to the CD8 T cell lineage coincided with down-reg-
ulation of GATA-3 expression. The most mature subpopulation of
uncommitted thymocytes, the CD41CD8low subset, contained
high numbers of GATA-3-expressing cells. During the maturation
of CD81 cells in the thymus, GATA-3 expression was gradually
lost. By contrast, GATA-3 expression remained high during differ-
entiation of CD41 cells in the thymus. Second, enforced GATA-3
expression inhibited the maturation of CD81 cells. The CD8 SP
fraction in the thymus contained increased numbers of apoptotic
cells and exhibited a selective deficiency of mature CD69lowHSAlow
cells. In the spleen and lymph nodes, the numbers of CD81 T cells
were significantly reduced.
Enforced expression of GATA-3 did not appear to directly in-
fluence the CD4 vs CD8 lineage cell fate decision, as in the CD2-
GATA3 mice the percentages of CD4 and CD8 SP cells in the
thymus were in the normal ranges. Although the molecular mech-
anisms underlying the developmental choice between CD4 and
CD8 T cell fates are not known, they are thought to depend on
differences in signal strengths of the MHC class I-CD8 and MHC
class II-CD4 interactions. The influence of signaling molecules on
lineage commitment is supported by the finding of differentiation
toward the CD4 lineage in a gain-of-function extracellular signal-
related kinase 2 mutant and in Csk- or C-Cbl-deficient mice (52–
54). Activated Notch transmembrane receptor or Bcl-2 overexpres-
sion was shown to promote differentiation to the CD8 lineage,
probably by rescue from apoptosis and development along the
CD8 lineage of cells that have a very low-affinity MHC interac-
tion, which would normally die by neglect (55–57).
Our data point at a role for GATA-3 in the maturation of the
cells once commitment has occurred. There is a progressive de-
cline of GATA-3 expression during CD8 lineage maturation, and
the enforced GATA-3 expression impaired cell survival in the most
mature CD8 lineage cells. Furthermore, peripheral CD81 T cells
from CD2-GATA3-transgenic mice manifested functional defects
in IL-2 and IFN-g production (see accompanying paper). In this
context, there is a striking parallel with Th1/Th2 differentiation,
where GATA-3 is expressed in naive peripheral T cells, followed
by a substantial increase during Th2 development and a gradual
down-regulation during Th1 development (24, 25). The Th2 phe-
notype is initiated by IL-4 signaling, and by the action of GATA-3
becomes stable over time and independent of extrinsic factors,
such as IL-4 (27, 29, 58). Retroviral tagging of naive progenitors
with GATA-3 provided direct evidence for instructive differenti-
ation, rather than selective outgrowth of committed Th1 or Th2
cells (26). It was further shown that GATA-3 generates stability of
Th2 commitment by chromatin remodeling of Th2-specific cyto-
kine loci, associated with a positive autoactivation pathway, which
is a recognized mechanism contributing to cell fate determination
(29). Concomitantly, GATA-3 inhibits Th1 development by re-
pressing IL-12Rb expression and, as a result, IL-12 induced IFN-g
production (59). Assuming a parallel role for GATA-3 in CD4/
CD8 and Th1/Th2 development, we propose that GATA-3 is in-
volved in the stabilization of the distinct gene expression profiles
in committed CD4 cells, whereas for the full maturation of CD8 T
cells, GATA-3 expression needs to be down-regulated. Alterna-
tively, GATA-3 may affect lineage commitment indirectly by in-
ducing higher TCRab expression levels (Fig. 6A), thereby increas-
ing the intensity of the signal delivered to DP cells, which has been
shown to skew development toward the CD4 lineage (60, 61). A
mechanism by which the influence of enforced expression of
GATA-3 on CD4/CD8 commitment is directly related to the pres-
ence of GATA-3 recognition sites in the CD8a promoter (62) can
also not be excluded. In that case, GATA-3 would have to directly
repress CD8 expression in mature cytotoxic T cells.
It is at present not clear why in CD2-GATA3 mice the levels of
transgene-encoded GATA-3 protein are down-regulated in CD8
SP cells and peripheral T cells. GATA-3 levels may be subject to
posttranslational regulation, as indicated by the presence of
caspase-mediated degradation of the closely related transcription
factor GATA-1 in immature erythroid cells (63). However, such a
mechanism should apply to both endogenous and transgene-en-
coded GATA-3. Therefore, the presence of the HA tag would then
affect posttranscriptional regulation.
Additional experiments will be needed to identify the critical
target genes for GATA-3 in early T cell development. Intriguingly,
GATA recognition sequences are present in the Notch4 promoter
region (64). If Notch genes would be regulated by GATA-3, this
could explain the parallels that exist between the in vivo function
of GATA-3 and Notch. Both genes are essential for the develop-
ment of the first stage of T cell development and not for any other
hemopoietic lineage (22, 31, 65). Apart from the accelerated
FIGURE 7. Enforced expression of GATA-3 in-
duces apoptosis and inhibits the maturation of
CD69lowHSAlow CD8 SP cells in the thymus. Thy-
mus cell suspensions were stained for CD4, CD8,
and annexin V (A) or TUNEL (B). Thymocytes were
analyzed for the expression for CD4 and CD8; the
indicated SP subpopulations were gated and ana-
lyzed for FSC and annexin V or TUNEL. The num-
bers indicate the percentage of annexin V-positive
(A) or TUNEL-positive (B) cells in the subpopula-
tions analyzed. C, In four-color flow cytometry ex-
periments, thymus cell suspensions were stained for
CD4 and CD8 expression along with anti-HSA and
anti-CD69 or with anti-CD62L and anti-CD44. The
CD4 and CD8 SP T cells were gated and analyzed
for the expression of the indicated markers. The re-
sults are displayed as histograms of CD2-GATA3-
transgenic mice (bold lines) along with those of non-
transgenic control mice (thin lines).
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TCRab up-regulation in developing CD691 thymocytes that
progress from the DP to the CD41CD8low stage, we did not see
any effects on the surface expression of presumed GATA-3 target
loci such as TCRa, b, and d or CD8a.
Our previous finding of low GATA-3 expression during the two
waves of TCR gene rearrangement, separated by a stage of high
GATA-3 expression, suggested a role of GATA-3 in the regulation
of proliferation events associated with the essential coupling of
V(D)J recombination activity to cell cycle (22). However, the ab-
sence of any detectable effects of the CD2-GATA3 transgene on the
cell cycle would argue against such an essential role for GATA-3.
Nevertheless, all thymic lymphomas in the CD2-GATA3 mice
characterized so far appeared to have originated at the DP stage, in
which all TCRa locus gene rearrangements occur. Therefore, it
remains possible that, in the presence of high levels of GATA-3,
oncogenic events, such as translocations, are mediated by aberrant
use of the V(D)J recombination machinery, as has been found in
V(D)J recombination-driven thymic lymphoma in mice deficient
for the ataxia telangiectasia gene (66).
Alternatively, the oncogenic potential of GATA-3 could be re-
lated to the ability of GATA-3 to form a complex with the TAL-1
and LMO transcription factors, which are implicated in a large
fraction of human T cell acute lymphoblastic leukemias (67). Nor-
mally TAL-1 and LMO are not expressed in the T cell lineage, but
expression is induced by translocation events. It was recently
shown that forced expression of GATA-3 in vitro potentiated the
induction by the TAL-1 and LMO transcription factors of retinal-
dehyde dehydrogenase 2, which inhibits apoptosis of T cells by
generating retinoic acid (67).
Also, enforced GATA-3 expression probably leads to increased
basal transcription of the RAD50 gene, which is involved in chro-
mosomal double-stranded break repair. Because of the localization
of the RAD50 gene within the IL-4/IL-5/IL-13 Th2 cytokine gene
cluster, an increase of basal RAD50 transcription is observed in
Th2 cells (27). It is possible that in the CD2-GATA3-transgenic T
cells the increase might be more extreme, thereby resulting in de-
stabilization of the MRE11-RAD50-NBS1 protein complex, which
is essential for chromosome stability (68).
Finally, a more general mechanism might be responsible for
the oncogenic effect of GATA-3, since GATA factors have a
key role in the regulation of development toward cell division
and differentiation via the cell cycle machinery (69). Recently
several other GATA family factors have been implicated in var-
ious human tumors, e.g., GATA-2 in acute promyelocytic leu-
kemia, acute myeloid leukemia, and myelodysplastic syndrome
and GATA-4 in esophageal adenocarcinomas and malignancies
of the gonads (70 –72). Further characterization of the tumor
cells should identify the possible involvement of any of these
oncogenic pathways in the origin of the thymic lymphomas in
the CD2-GATA3 mice.
In conclusion, this study adds to our knowledge of the function
of GATA-3 in early T cell development because we have estab-
lished a correlation between GATA-3 expression and maturation
toward the CD4 vs the CD8 lineage. We propose that in early T
cell development, expression of GATA-3 is essential for the main-
tenance of CD4 cell lineage fate commitment, but inhibits CD8
differentiation. Inferred from the recent findings that GATA-3 acts
a key regulator of Th2 development by stabilizing patterns of gene
expression, it is attractive to hypothesize that in early T cell de-
velopment GATA-3 would stabilize, by chromatin remodeling, the
unique gene expression profiles that are characteristic for the CD4
lineage.
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